Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07135687 · ClinicalTrials.gov registry record · Phase 4
Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction
A Phase 4 study, sponsored by Rush University Medical Center.
- Not yet
- Registry status
- Phase 4
- Development phase
- 144
- Enrollment target
NCT07135687: Clinical Trial Phase 4 study, sponsored by Rush University Medical Center.
NCT07135687 is a Phase 4 study that has not yet begun recruiting, run by Rush University Medical Center. The registered enrollment target is 144 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07135687, a Phase 4 study, has not yet begun recruiting, sponsored by Rush University Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 144 participants
- Enrollment target
Study Summary
The purpose of this study to investigate the effect of using losartan (a blood pressure lowering drug with anti-scarring properties) on preventing primary postoperative arthrofibrosis (formation of abnormal scar tissue) in the knees in participants undergoing anterior cruciate ligament (ACL) repair surgery of their knee.
Primary Outcome
Range of motion measured from baseline to 12 months
Interventions
- OTHER Placebo
- DRUG Losartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2026-08 |
| Est. Completion | 2028-12 |
| Phase | Phase 4 |
What is known before NCT07135687 opens enrollment
NCT07135687 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07135687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07135687 about?
NCT07135687 is a clinical study titled "Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction". The purpose of this study to investigate the effect of using losartan (a blood pressure lowering drug with anti-scarring properties) on preventing primary postoperative arthrofibrosis (formation of abnormal scar tissue) in the knees in participants undergoing anterior cruciate ligament (ACL) repair ...
What is the current status of trial NCT07135687?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 144 participants. The study started on 2026-08. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07135687?
The interventions under investigation include: Placebo (OTHER), Losartan (DRUG).
Who is sponsoring clinical trial NCT07135687?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07135687's enrollment target sits among peer trials
144 577th of 2000 higher than 1,421 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia